
Index

A

Acetylcholine, 8
Alcohol-use disorder, 35, 36, 40
Anhedonia, 28, 218
Anticonvulsants, 45
Antidepressant monotherapy, 42, 43
Antidepressants, 42, 43, 45, 46, 98, 99, 160
Antiepileptic drugs (AEDs)
 mood effects, 128
 psychiatric side effects, 128, 129
 treatment-emergent psychiatric adverse events, 129
 and suicidality, 127, 128
Antipsychotic medications, 46
Anti-suicidal efficacy, 45
Anxiety disorders, 35, 42, 131
 medical student suicide, 253, 254
 symptoms, 196
Anxiolytics, 33, 46, 96, 110
Attention-deficit hyperactivity disorder (ADHD), 35, 123, 253
AUDIT-C screening tool, 257
Autism spectrum disorder (ASD), 83
Autoimmunity, 14

B

Beck Depression Inventory, 182, 242–244, 258
Beck Scale for Suicide Ideation (BSI), 40, 59, 74
Behavioral health consultants (BHCs), 161–168
Benzodiazepines, 63, 199, 279
Benzotropine, 63
BHC, *see* Behavioral health consultants (BHCs)
Biomarkers, 6, 10, 117

Bipolar disorder, 23, 32
 anticonvulsants, 45
 antidepressants, 45, 46
 antipsychotic medications, 46
 epidemiology, 24
 lithium, 44, 45
 medications, 44
 protective factors, 32
 type 1 and type 2, 32
Borderline personality disorder, 33, 36, 42
BPRS suicidality index, 13
Brain-derived neurotrophic factor (BDNF)
 gene, 9, 13, 14, 25
Brief suicide safety assessment (BSSA), 89–91
Buprenorphine, 113

C

Calgary Depression Rating Scale (CDRS), 58, 59
Cardiovascular disease, 37, 38, 42
Catechol-O-methyltransferase (COMT)
 gene, 25
CBT, *see* Cognitive behavioral therapy (CBT)
Center for Epidemiologic Studies Depression (CES-D) Scale, 258
Centers for Disease Control and Prevention (CDC), 56, 175, 229
Child Behavior Checklist, 134
Child Depression Inventory-2, 134
Childhood-onset epilepsy, 127
Children, suicide in
 consent/legal/confidentiality, ability to, 100, 101
 developmental trajectories, 73
 documentation, 101

- Children, suicide in (*cont.*)
- epidemiology
 - 5–11 years age, 76
 - 10–14 years age, 76, 77
 - 15–19 years age, 77
 - 19–24 years age, 77
 - in United States, 75
 - laboratory evaluation, 97
 - management, 97, 98
 - patient physical examination, 97
 - protective factors
 - definition, 84
 - effective coping strategies, 85
 - internal locus of control, 85
 - religiosity, 86
 - social connectedness, 85
 - resources, 101
 - risk factors
 - academic pressure, 82, 83
 - acute stressors, 74
 - ASD/ID, 83
 - assessment and management,
 - implication of, 84
 - bullying, 82
 - childhood trauma, 81
 - comorbid psychiatric conditions, 73
 - depression, 78
 - developmental trajectories, 74
 - environmental factors, 74
 - family factors, 80
 - gender identity, 82
 - medical illness, 83, 84
 - previous suicide attempt, 78, 79
 - protective factors, 74
 - psychopathology, 78
 - sexual orientation, 81, 82
 - substance use disorders, 79, 80
 - suicidal behaviors, familial
 - transmission of, 80
 - suicidal risk screening, 86–88
 - components, 89
 - cultural considerations, 88
 - tools, 87–89
 - suicide risk assessment
 - BSSA, 89–91
 - developmental considerations, 96, 97
 - mental health evaluation, 96
 - treatment
 - antidepressants, 98
 - CBT, 98
 - electroconvulsive therapy, 98
 - Family-based Crisis Intervention, 99
 - ICBT, 99
 - ketamine, 98
 - longer-term perpetuating or predisposing factors, 98
 - non-invasive neuromodulation, 98
 - safety plan, 100
 - SAFETY Program, 99
 - SSRI and suicidality, 99, 100
 - Chronic pain, 37, 143, 175, 293
 - emotional pain, 144, 145
 - neurobiology of, 144
 - physical pain, 144, 145
 - psychological risk factors, 145
 - suicide, management of, 148–149
 - vulnerable groups
 - comorbid medical conditions, 146, 147
 - personality characteristics, 146
 - psychiatric comorbidities, 145, 146
 - vulnerable time periods, 147
 - warning signs, 147, 148
 - Chronological Assessment of Suicide Events (CASE) approach, 267, 268
 - Chronotherapy, 48
 - Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE), 64
 - Clinical Global Impression (CGI), 58
 - Clinical Global Impression for Severity of Suicidality (CGI-SS), 59
 - Collaborative assessment and management of suicidality (CAMS), 85, 197, 198
 - Clonazepam, 63
 - Clozapine, 64, 187
 - Cognitive behavioral therapy (CBT), 42, 61, 62, 98, 114, 134, 211
 - Cognitive Behavior Therapy for Suicide Prevention (CBT-SP), 99
 - Cognitive disorders, 29, 196
 - Cognitive empathy, *see* Empathic Accuracy (EA)
 - Cognitive load theory, 235, 236
 - Collaborative Assessment and Management of Suicidality (CAMS), 99
 - Columbia Suicidality Screen Rating Scale (CSSR-S), 13
 - Columbia Suicide Severity Rating Scale (C-SSRS), 58, 59, 89, 133, 156–158, 181, 182, 210
 - Comfort care, 194
 - Comorbid medical conditions, 146, 147
 - Comprehensive Psychopathological Rating Scale (CPRS), 61

- Confirmatory factor analysis (CFA), 243
 Cortisol, 27
 C-reactive protein (CRP), 12, 26, 27
 C-SSRS, *see* Columbia Suicide Severity Rating Scale (C-SSRS)
 Cyclic adenosine monophosphate response element-binding protein-1 (CREB1) gene, 26
 Cytokines, 10, 11
- D**
 Delirium, 196, 197
 Depressive disorders, 78, 114, 145, 289, 290, 293–295
 MDD, 32
 medical student suicide, 252, 253
 symptom, 32, 196
 Dexamethasone suppression test (DST), 6
 Dialectical behavior therapy (DBT), 42, 211, 281
 Dignity therapy, 199, 200
 Disrupted mood dysregulation disorder (DMDD), 23
 Domestic violence, 112
 Dopamine, 8, 100
 Drug Abuse Screening Test (DAST), 258
 Duloxetine, 198
- E**
 Eating Disorder Examination Questionnaire (EDE-Q), 258
 Edinburgh Postnatal Depression Scale (EPDS), 156, 157
 EEG sleep parameters, 28
 Electroconvulsive therapy (ECT), 47, 48, 98
 Emergency department (ED)
 managing at-risk patients, 186
 suicidal ideation and attempts, treatment for, 186, 187
 suicide prevention
 ED-SAFE patient safety screener, 182, 183
 preventive measures, 185, 186
 Safe-T test, 183, 184
 smartphone tools, 183
 suicide risk factors
 age, sex, gender and race, 174, 175
 assessment tool, 177–182
 family history and genetics, 176
 health, 175
 mental disorders, 174
 occupation, 175
 predisposing factors, 174
 previous suicide attempts, 78, 79, 174
 protective factors, 176
 sense of isolation, 175
 Emotional pain, 144, 145
 Empathic Accuracy (EA), 237
 Empathy, 236, 237
 EPDS, *see* Edinburgh Postnatal Depression Scale (EPDS)
 Epilepsy
 age of, 126
 antiepileptic drugs, 126
 cortisol hormone, 131
 diagnosis, 126, 130
 duration of, 126
 executive dysfunction, 124, 125
 hyperexcitability, inhibitory effect, 131
 Iceland-based population study of adults and children, 130
 incidence rate ratio, 130
 interleukin-1 β , 131
 with mood disorders, 128
 mortality risk, 126
 neurobiological pathogenic pathways, 131
 pathogenesis processes, 132
 population-based study, 130
 prevalence ratio, 130
 proinflammatory cytokines, 131
 psychiatric comorbidities, 123–124, 129
 psychiatric disorders, 127, 130
 seizure disorder, 126, 129
 seizure freedom, 127
 serotonin receptor binding, brain, 131
 suicidal behavior
 psychosocial interventions, 134, 135
 screening and prevention, 132–134
 suicidal ideation, 126
 surgery, 127
 TLE, 125, 126
 treatment-resistant focal seizures, 126
 Euthanasia, 194
 Expressing deep emotion (EMO), 260
- F**
 Family-based Crisis Intervention, 99
 First-episode psychosis (FEP), 54, 59
 Fluoxetine, 43
 Focal refractory epilepsy, 125

G

- Gatekeeper Behavior Scale (GBS), 243
- Gatekeeper training, 235
 - At-Risk in ED* simulation
 - evaluation, 244–246
 - means efficacy, 244, 246
 - measures, 243, 244
 - At-Risk in Primary Care*, 238
 - evaluation, 238, 239
 - means efficacy, 240, 241, 243
 - completion time and fidelity, 242
 - innovative virtual human gatekeeper
 - simulation technology, 231
- Kognito Behavior Change Model (*see* Kognito Behavior Change Model)
 - means efficacy, 241
 - measures, 238
 - simulation works, 233–235
 - student status as moderator, 241
 - virtual humans, 231–233
- Generalized Anxiety Disorder-7 (GAD-7), 133
- Genetic polymorphisms, 25, 26
- Global Severity Index of the Brief Symptom Index (GSI-BSI), 63

H

- Hamilton Rating Scale for Depression (HAM-D), 58
- Hastened death, desire for, 193
- Healer Education Assessment and Referral (HEAR) program, 257, 258
- Healthcare Effectiveness Data and Information Set (HEDIS), 212–213
- Heavy episodic drinking (HED), 79
- Helplessness, 60, 134, 147, 182
- Henry Ford Health System (HFHS), 208
- High-risk construct scale, 178
- Hopelessness, 60, 147, 148, 172, 182, 254
- Hospital-based care, 226
 - constant observation, 223, 224
 - high-risk patients, 218, 219
 - hospitalized patients attempt suicide, 219, 220
 - inpatient units, risk and strategies
 - guidelines, 220
 - medical-surgical units issue, 221
 - personnel, 220, 221
 - psychiatry units issue, 221, 222
- JCAHO, 217
 - sitters, alternatives to, 224, 225
- Hypothalamic-pituitary-adrenal (HPA) axis, 11, 14, 117
- Hypothalamic-pituitary-adrenal (HPA)-cortical axis stress response, 27

I

- Individual inflammatory markers
 - C-reactive protein, 12
 - cytokines, 10, 11
 - IFN-gamma, 12
 - IL1-B, 11
 - IL-2, 11
 - IL-6, 11
 - KYNA, 12
 - QUIN, 12
 - S100B, 12
 - BDNF, 13, 14
 - BPRS suicidality index, 13
 - Orexin, 14
 - VEGF, 14
 - TNF-alpha, 11
- Inflammatory theories, 26
- Innovative virtual human gatekeeper
 - simulation technology, 231
- Insomnia, 28, 42, 148, 279
- Integrated Cognitive Behavior Therapy (ICBT), 99
- Intellectual disabilities (ID), 83
- Intensive psychiatric observation, 223
- Interferon (IFN) gamma, 12
- InterSePT Suicide Scale (ISST), 59

K

- Ketamine, 46, 47, 98, 187
- Kognito Behavior Change Model
 - cognitive load theory, 235, 236
 - components of, 235
 - EA, 237
 - empathy, 236, 237
 - mentalizing, 236
 - MI, 236
 - RS, 237
 - SM, 237
- Kognito Conversation Platform™, 235
- Kynurenic acid (KYNA), 12

L

- Lorazepam, 63, 199

M

- Major depressive disorder (MDD), 26, 34
 - antidepressants, 42, 43
 - BRIDGE-MIX study, 33
 - comorbidity of, 34
 - cytokines, 10
 - dopamine, 8
 - lithium, 44

- prevalence rates, 23
 - risk factors, 32
 - Maladaptive defenses, 198
 - Manchester self-harm rule and ReACT
 - self-harm rule, 178
 - MDD, *see* Major depressive disorder (MDD)
 - Meaning-centered psychotherapy, 200
 - Medical student suicide
 - anxiety, 253, 254
 - burnout, 255, 256
 - curricular events, 255
 - depression, 252, 253
 - environmental factors, 255
 - familial behaviors, 255
 - HEAR protocol, 258
 - marital status, 256
 - prevalence and surrounding circumstances, 251, 252
 - prevention, 258–260
 - race, 256
 - sex, 254
 - substance abuse, 257
 - suicidal ideation, 252, 258
 - Mental disorders, 174, 193, 198, 273
 - Mental health and substance abuse (MHSA), 84
 - Mental illness, 110, 290, 294, 297
 - Mentalizing, 223, 236
 - Mercy killing, 193
 - Methadone, 113
 - Michigan Alcoholism Screening Test (MAST), 258
 - Mini International Neuropsychiatric Interview (MINI), 133
 - Mitogen-activated protein kinase 1 (MAPK1)
 - gene, 25
 - Modified version of the SAD PERSONS scale (MSPS), 178, 179
 - Mood disorders, 110, 111, 131
 - anxiolytics and sedatives, 46
 - biological factors
 - genetic polymorphisms, 25, 26
 - inflammatory theories, 26
 - neuroanatomical correlates, 26
 - neurotransmitter dysregulation, 25
 - physiological response to stress, 27
 - sleep, 28
 - bipolar disorder, 23
 - anticonvulsants, 45
 - antidepressants, 45, 46
 - antipsychotic medications, 46
 - lithium, 44, 45
 - medications, 44
 - chronotherapy, 48
 - clinical testing of vitamin D levels, 47
 - depressive disorders, 23, 289, 290
 - early diagnosis and intervention, 41
 - etiological theories, 24
 - ketamine, 46, 47
 - level of care, 42
 - modifiable risk factors, 41
 - neurostimulation
 - ECT, 47, 48
 - rTMS, 47
 - primary health care, 41
 - psychological factors, 28, 29
 - psychological treatments, 42
 - risk assessment, 38–40
 - risk factors, 32
 - risk factors for suicide, 32
 - ADHD, 35
 - anxiety disorders, 35
 - cardiovascular disease, 37, 38
 - chronic illnesses, 37
 - depressive polarity, 33
 - family history, 31
 - first depressive episode, 34
 - personality disorder, 36, 37
 - prior suicide attempt, 30
 - prior suicide attempts, 33
 - severe depression, 33
 - sociodemographic features, 31
 - sociodemographic risk factors, 31
 - substance-use disorder, 35, 36
 - trauma-related disorders, 34, 35
 - social/environmental factors, 29, 30
 - TCT, 48
 - Motivational interviewing (MI), 236
 - Multisystemic Therapy-Psychiatric (MST-P), 62, 63
- N**
- National Suicide Prevention Lifeline, 208
 - Neurobiology of suicide, 5, 6, 10
 - acetylcholine, 8
 - autoimmunity, 14
 - BDNF, 9
 - biomarkers, 6
 - clinical predictors of, 4, 5
 - dopamine, 8
 - epidemiology, 3, 4
 - estimation, 285
 - individual inflammatory markers (*see* Individual inflammatory markers)
 - neuroinflammatory markers, 9, 10
 - neurotrophins, 8
 - noradrenergic system, 7, 8
 - serotonin, 6, 7
 - Toxoplasma gondii*, 14

- Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), 133
- Neuropathic pain, 147, 184
- Neurostimulation, 47–48
- Neurotransmitter dysregulation, 25
- Neurotrophins, 8, 9, 13
- Nonfatal suicidal thoughts and behaviors, 75
- Non-suicidal self-injury, 75
- Noradrenergic system, 7, 8
- O**
- Olanzapine, 199
- Orexin, 10, 14
- Orygen program, 61
- Overlap matrix model, 176
- P**
- Palliative care
- comfort care, 194
 - compassionate care, 200, 201
 - dignity therapy*, 199, 200
 - ethical aspects, 195
 - euthanasia, 194
 - hastened death, desire of, 193
 - historical aspects, 191–193
 - management of patients, 198, 199
 - meaning-centered psychotherapy, 200
 - palliative chemotherapy, 194
 - physician-assisted suicide, 193
 - suicidal ideation, 193
 - suicidal intent/plan, 193
 - suicide risk evaluation, factors in, 195
 - cognitive disorders, 196
 - delirium, 196, 197
 - depressive and anxiety symptoms, 196
 - fear of losing control, 196
 - maladaptive defenses, 198
 - mood and anxiety symptoms, 197
 - pain, 195, 197
 - physical symptoms, 195
 - psychiatric disorders, 198
 - psychiatric history, 197
 - social support, 196, 198
 - somatic symptoms, 197
 - spiritual and existential concerns, 197, 198
- Palliative chemotherapy, 194
- Parasympathetic nerve system (PNS), 27
- Patient Health Questionnaire-9 (PHQ-9), 133, 156
- vs. C-SSRS, 157, 158
 - vs. EPDS, 156, 157
- PCBH, *see* Primary Care Behavioral Health (PCBH) model
- Persistent depressive disorder (PDD), 23
- Personality disorders, 7, 36, 37, 160, 184
- PHQ-9, *see* Patient Health Questionnaire-9 (PHQ-9)
- Physical pain, 144, 145
- Physician-assisted suicide, 193
- Positive and Negative Syndrome Scale (PANSS), 58
- Posttraumatic stress disorder (PTSD), 34, 225
- Primary Care Behavioral Health (PCBH) model
- BHCs, 161–163
 - population-based care, 162
 - rationale, 161, 162
 - suicide management
 - care management, 168
 - documentation, 165, 166
 - high-risk patients, 165
 - imminent-risk patients, 165
 - low-risk patients, 165
 - moderate-risk patients, 165
 - in practice, 166
 - risk assessment, 163, 164
 - risk assessment and intervention, 167, 168
 - screening, 163
 - screening/prevention, 166, 167
- Psychiatric comorbidities, 145, 146
- Psychiatric disorders, 78, 174, 198
- Psychiatric interviewing
- CASE approach, 267, 268
 - complementary interview skills, 268, 269
 - countertransference, 269
 - suicide assessment, 267
- Psychiatry residency training
- prevention, prediction to, 275, 276
 - suicide postvention approaches
 - emotional and psychological response, 276, 277
 - interventions with trainees, 277, 278
 - prevalence, 276
 - suicide prevention education
 - consensus guidelines, 272, 273
 - management core competencies, 278, 280–282
 - in primary care residency and fellowship training programs, 274
 - public health approach, 273, 274
 - suicide risk assessment, 267
 - academic training, 266

- APA practice guidelines, 270
 clinical vignettes, 271
 popular film, 271
 psychiatric interviewing (*see*
 Psychiatric interviewing)
 role-playing and standardized patients,
 271, 272
 RRSR clinical training program, 270
 video-recorded patient interviews, 271
 VP, 272
- Psychoeducation, 42, 60, 63, 64
- Psychosis**
 assessment, 57, 58
 C-SSRS, 58, 59
 early intervention, 60, 61
 ISST, 59
 management of, 63, 64
 MST-P, 62, 63
 protective factors, 56, 57
 schizophrenia (*see* Schizophrenia)
- Psychosocial interventions, 134, 135
- Q**
- Quinolinic acid (QUIN), 12
- R**
- Reappraisal Strategy (RS), 237
 Repetitive transcranial magnetic stimulation
 (rTMS), 47
 Resilience Scale (RS), 259
- S**
- SA, *see* Suicide attempts (SA)
 SAD PERSONS scale, 177
 SAFETY Program, 99
 Scale for Suicide Ideation (SSI), 40
- Schizophrenia**
 CATIE, 64
 CBT, 61, 62
 CDRS, 58
 clozapine, 64
 cognitive factors, 53
 expressed emotion, 65
 FEP, 54, 55
 HAM-D score, 58
 incidence of, 53
 negative symptoms, 53
 PANSS, 58
 positive symptoms, 53
 psychoeducation, 60
 risk factors, 55–56
 SSRS, 58
 suicide and, 54
 treatment, 59, 60
 treatment-resistant schizophrenia, 64
- Schizophrenia Suicide Risk Scale (SSRS), 58
- Sedatives, 46
- Seizure disorders, 131
- Selective serotonin reuptake inhibitors
 (SSRIs), 10, 43, 99, 100, 118
- Self-Compassion Scale (SCS), 259
- Sense of Coherence (SOC) Scale, 258
- Sentinel Event Alert (SEA), 206
- Serotonin, 6, 7
- Serotonin transporter (SERT), 7
- Sertraline, 43
- Sexual and gender minority (SGM), 81
- SI, *see* Suicidal ideation (SI)
- Single nucleotide polymorphisms (SNPs), 26
- Situation Modification (SM), 237
- Sleep deprivation, 148, 182, 282
- State-Trait Anxiety Inventory for Adults
 (STAIA), 258
- SSRI, *see* Selective serotonin reuptake
 inhibitors (SSRIs)
- Substance abuse**
 medical student suicide, 257
 warning sign, 295
- Substance Abuse and Mental Health Services
 Administration (SAMHSA), 28, 58,
 206, 208
- Substance use disorders, 28, 33, 35, 36
 alcohol use, 111
 acute, 111
 aggression and serotonin deficiency,
 112
 chronic, 110
 impulsivity, 111
 mood disorders, 111
 and suicidal behavior, 112
 treatment, 112
 violent behavior, 111, 112
- in children, 79, 80
- cocaine, 114
- cost, 110
- definition, 109
- mental illness, 110
- mood disorders, 110
- opioid drugs, 112, 113
 physician suicide, 290, 291
- Subthreshold bipolarity, 43
- Sudden unexpected death in epilepsy
 (SUDEP), 120, 132

- Suicidal behavior, 25, 30, 32, 39
 antidepressant, 46
 antiepileptic medications, 45
 cortisol, 27
 decision-making impairment, 29
 insomnia, 28
 lithium, 45
 MDD, 30
 motivational-volitional model, 29
 risk factors for, 33
 risk for, 37
 risk of, 24
- Suicidal Behaviors Questionnaire-Revised (SBQ-R), 58
- Suicidal ideation (SI), 33, 39, 88, 193, 195, 197
 alcohol use, 111
 cardiovascular disease, 37
 depressive symptomatology and hopelessness, 40
 development of, 39
 ECT course, 47
 emergency department, 186, 187
 HPA axis activity, 27
 HTR2A gene, 26
 ketamine, 47
 medical student suicide, 252
 polysomnography sleep parameters, 28
 pre-motivational factors, 30
 PTSD, 34
 primary care, 155
 risk of, 4, 175
 scales for assessment, 40
 social isolation, 29
 substance-use disorders, 35
- Suicidal thinking, *see* Suicidal ideation
- Suicide assessment five-step evaluation and triage test (Safe-T test), 183, 184
- Suicide assessment scale (SUAS), 178
- Suicide attempts (SA), 5, 24, 39–41, 44, 45
 ADHD, 35
 in adolescents, 4, 5
 in bipolar disorders, 24
 comorbid psychiatry diagnoses, 33
 cortisol, 27
 CPR, 27
 CSF 5HIAA, 7
 family history, 31
 HTR2A gene, 26
 neuroinflammatory markers, 9, 10
 physician suicide, 291
 risk of, 4, 25, 30
 social minority, 31
 trauma, 34
- Suicide death, 99, 191, 193, 200
 estimation of, 173
 incidence of, 70
- Suicide prevention, 41
 healthcare, 205, 209
 core values, 208
 Evidence-Based Clinical Care Practice, 208
 HFHS, 208
 mental healthcare, 205, 207
 National Suicide Prevention Lifeline, 208
 PHQ-9 screening questionnaire, 207
 SAMHSA, 206, 208
 SEA, 206
 systems management, 208
 Zero Suicide approach (*see* Zero Suicide approach)
- primary care, 161
 antidepressants, 160
 education and training on suicide in medical school, 158
 individual factors influencing suicide assessment and treatment, 159, 160
 PCBH (*see* Primary Care Behavioral Health (PCBH) model)
 PCP and suicide risk assessment, 158, 159
 training, benefits of, 160, 161
- Suicide risk
 for alcohol dependence, 111
 in children, 73
 in ED
 age, sex, gender and race, 174, 175
 assessment tool, 177–182
 family history and genetics, 176
 health, 175
 mental disorders, 174
 occupation, 175
 predisposing factors, 174
 previous suicide attempts, 174
 protective factors, 176
 sense of isolation, 175
 for physician suicide, 286–288
 alcohol/substance abuse, 290, 291
 clinical errors, blame for, 292
 high-risk activities, 292
 lethal means, access to, 291
 marital problems, 289
 mood disorder, 289, 290
 perfectionism and the competitiveness, 292
 previous self-harm/suicide attempts, 291

race, 289
sex, 288, 289
screening for, 155, 156
vs. warning signs, 286, 287
Suicide Status Form (SSF), 40
Systematic treatment enhancement program
for bipolar disorder (STEP-BD), 38

T

Temporal lobe epilepsy (TLE), 125, 126
Toxoplasma gondii, 14
Trauma-related disorders, 34, 35
Triple chronotherapy (TCT), 48
Tumor necrosis factor alpha (TNF-alpha), 11

U

Unipolar depression, 44
U.S Preventive Services Task Force
(USPSTF), 155, 158

V

Vascular endothelial growth factor (VEGF), 14
Venlafaxine, 198
Violence and suicide assessment scale,
179–180
Virtual patient (VP) technology, 272
Vitamin D, 27

W

Warning signs
for physician suicide, 287
alcohol/drug consumption, 295
depression, 293–295
divorce rates, 294
financial hardships, legal difficulties
and public humiliation, 297
marital disruption, 294
medication, 295, 296
pain, 293
stresses, 296
substances with lethal outcomes, 295,
296
vs. risk factors, 286–287
Wenzel and Beck's model, 148

Y

Youth Risk Behavior Surveillance System
(YRBSS), 77, 81, 82
Youth Risk Behavior Survey (YRBS), 63

Z

Zero Suicide approach
safety evidence-based treatment, 211, 212
safety planning intervention, 210, 211
screening and assessment, 209, 210
supportive contacts, 212, 213